AstraZeneca says drug combo meets goal in late-stage ovarian cancer trial – ET HealthWorld

Bengaluru: AstraZeneca on Wednesday stated a mixture of its most cancers medicine Imfinzi and Lynparza met the principle purpose in a late-stage trial in sufferers with superior ovarian cancer.

The drugmaker stated remedy with a mixture of these medicine, together with chemotherapy and bevacizumab – the present customary of care – improved progression-free survival in newly identified sufferers with superior ovarian most cancers with out sure mutations.

Lynparza, collectively developed with US-based Merck & Co , was authorized final yr by the US Food and Drug Administration as a remedy for early-stage breast most cancers with sure mutations.

Imfinzi alone, together with chemotherapy and bevacizumab, didn’t attain statistical significance in its interim evaluation, the drugmaker added.

  • Revealed On Apr 5, 2023 at 04:36 PM IST

Be part of the neighborhood of 2M+ trade professionals

Subscribe to our e-newsletter to get newest insights & evaluation.

Obtain ETHealthworld App

  • Get Realtime updates
  • Save your favorite articles

Scan to obtain App

Image / Information Source

Leave a Reply

Your email address will not be published. Required fields are marked *